Bureau Veritas SA : The stock forcefully approaches new pivot levels
Entry price | Target | Stop-loss | Potential |
---|
€21.95 |
€24.6 |
€21.3 |
+12.07% |
---|
Bureau Veritas shares are trading close to a major resistance level. Given the share's technical chart pattern, investors could anticipate that this resistance zone will be broken which could lead to new upside potential.
Summary● The company has solid fundamentals for a short-term investment strategy.
Strengths● The company returns high margins, thereby supporting business profitability.
● Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● With a 2019 P/E ratio at 24.78 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.